[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641166":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":45,"centralContacts":49,"locations":55,"responsibleParty":76,"collaborators":78,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":89,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":36,"studyType":95,"phases":96,"briefSummary":98,"conditions":99,"keywords":101,"overallStatus":58,"whyStopped":36,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":114},{"fullName":5,"class":6},"King's College London","OTHER",[8,14,20,25],{"label":9,"type":10,"description":11,"interventionNames":12},"2.5mg THC","EXPERIMENTAL","2.5mg tetrahydrocannabinol oil",[13],"Drug: THC",{"label":15,"type":16,"description":17,"interventionNames":18},"300mg CBD","ACTIVE_COMPARATOR","300mg cannabidiol oil",[19],"Drug: CBD",{"label":21,"type":16,"description":22,"interventionNames":23},"2.5mg THC + 300mg CBD","2.5mg THC + 300mg CBD (Combined arm)",[24],"Drug: THC + CBD",{"label":26,"type":27,"description":28,"interventionNames":29},"Placebo","PLACEBO_COMPARATOR","Placebo oil",[30],"Drug: Placebo",[32,37,40,43],{"type":33,"name":34,"description":11,"armGroupLabels":35,"otherNames":36},"DRUG","THC",[9],null,{"type":33,"name":38,"description":17,"armGroupLabels":39,"otherNames":36},"CBD",[15],{"type":33,"name":41,"description":21,"armGroupLabels":42,"otherNames":36},"THC + CBD",[21],{"type":33,"name":26,"description":28,"armGroupLabels":44,"otherNames":36},[26],[46],{"name":47,"affiliation":5,"role":48},"Will Lawn, PhD","PRINCIPAL_INVESTIGATOR",[50],{"name":51,"role":52,"phone":53,"phoneExt":36,"email":54},"Catherine I V Bird, MSc","CONTACT","+44(0)2032281590","catherine.bird@kcl.ac.uk",[56],{"facility":57,"status":58,"city":59,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"The Centre for Mental Health Research and Innovation","RECRUITING","London","SE5 8BB","United Kingdom","UK",{"type":64,"coordinates":65},"Point",[66,67],-0.12574,51.50853,{"lat":67,"lon":66},[70,72,73],{"name":71,"role":52,"phone":53,"phoneExt":36,"email":54},"Catherine Bird",{"name":47,"role":48,"phone":36,"phoneExt":36,"email":36},{"name":74,"role":75,"phone":36,"phoneExt":36,"email":36},"James JH Rucker, MRC Psych, PhD","SUB_INVESTIGATOR",{"type":77,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR",[79],{"name":80,"class":6},"South London and Maudsley NHS Foundation Trust","100641166","challenging-the-endocannabinoid-system-in-sleep-restricted-healthy-volunteers-to-modulate-physiological-arousal-canisleep-study-100641166",false,"NCT07656350","Challenging the Endocannabinoid System in Sleep Restricted Healthy Volunteers to Modulate Physiological Arousal (CANISLEEP) Study","CANISLEEP","Inclusion Criteria:\n\n1. Aged 18-60\n2. Currently experiencing higher than average anxiety (measured by a score of ≥10 on the GAD-7)\n3. Able and willing to restrict their sleep to 4 hours on one occasion\n4. Willing to restrict alcohol and recreational drug intake during time on the study, confirmed by negative urine drug screen on the day of the experimental session\n5. Own a functioning phone and be able to respond to text messages\n6. Willing to provide GP details\n7. Willing to provide an emergency contact\n8. Able to provide written informed consent\n9. Willing to use a highly effective contraceptive method (see Section 5.2.2) for the duration of the study.\n\nExclusion Criteria:\n\n1. Currently receiving any treatment for any psychiatric disorder (medication and\u002For professional psychotherapy for a mental disorder)\n2. Any cannabinoid use in the past 3 months, including CBD oil, medical cannabinoids or recreational cannabis\u002FTHC use\n3. Cannabinoid contraindications: lifetime history of psychosis, 1st degree relative with psychosis, lifetime substance use disorder (that was professionally treated)\n4. History of consistent (\\>12 months) monthly cannabis use\n5. Currently experiencing insomnia or irregular sleep pattern (e.g. night shift work)\n6. Sleep restriction contraindications (sleep apnoea, sleep movement disorder, night shift work, insomnia)\n7. Have excessive daily caffeine intake (\\>4 cups of coffee per day or equivalent)\n8. Unlikely to be able to complete the study procedures for any reason, as judged by the study team\n9. Currently pregnant or lactating\n10. Currently trying to conceive a child\n\nAdditional criteria which must be met on experimental visits:\n\n1. Negative urine drug screen\n2. Negative urine pregnancy test\n3. Negative alcohol breath test",true,"ALL","18 Years","60 Years",{"count":93,"type":94},60,"ESTIMATED","INTERVENTIONAL",[97],"NA","The goal of this study is to learn about the body's response to cannabis based products in sleep deprived people who are currently experiencing anxiety but are otherwise healthy.",[100],"Healthy Volunteer",[34,38,102,103,104],"Cannabis","Stress","Anxiety","2026-06-15",{"date":107,"type":108},"2026-06-18","ACTUAL",{"date":110,"type":108},"2026-06-02",{"date":112,"type":94},"2027-12-31",{"name":5,"class":6},1]